Merck & Co. has secured a seat at the productive Daiichi Sankyo antibody-drug conjugate (ADC) factory. While AstraZeneca picked up the first two ADCs off the production line, its rival and ...
Fatima Attarwala is a business news writer and editor with a decade of experience researching, analyzing, and commenting on issues influencing the economy. Bloomberg / Contributor / Getty Images Merck ...
A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, boosting plans to take a second shot at FDA approval. But two more people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback